The Universally Accessible Cheaper and Quality Medicines Act of 2008 has succeeded in bringing down the cost of essential drugs and those to treat chronic diseases in The Philippines.
The coming into force on July 4, 2008 of Republic Act No. 9502, known as the Universally Accessible Cheaper and Quality Medicines Act of 2008, has succeeded in bringing down the cost of essential drugs and those to treat chronic diseases.
On the other hand, because of the desire of the courts to help the poor gain access to cheaper medicine, it also resulted in incorrect jurisprudence. The decision of the Supreme Court in the case of Roma Drug v GlaxoSmithKline which was promulgated on April 16, 2009 neglected to consider the more important objective of the law to ensure that the quality of medicine is not compromised.
Roma Drug imported Augmentin, Orbenin, Amoxil and Ampiclox, which it sold without obtaining prior registration from the Bureau of Food and Drugs (BFAD), now the Food and Drug Administration (FDA). The BFAD registrations of these drugs were made by GlaxoSmithKline.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Pharmaceuticals, SLCD
